Charles McDermott

Charles (Charlie) McDermott has more than 24 years of experience in the life sciences industry and has held roles of increasing responsibility in drug discovery, regulatory affairs, corporate development, commercial planning, and executive management. Most recently Mr. McDermott was President, Chief Business Officer, and a member of the board of directors of Impact Biomedicines, Inc. While at Impact, Mr. McDermott raised more than $110 million in private equity and royalty financing to fully fund the development and commercialization of fedratinib for the treatment of serious hematological malignancies. Impact was acquired by Celgene in 2018 for $1.1 billion upfront and up to $7 billion overall, if all contingent payments are realized. Prior to joining Impact, Mr. McDermott was President and Chief Business Officer of Kala Pharmaceuticals, Inc. Mr. McDermott helped lead the transformation of Kala from a private pre-clinical stage company to a pre-commercial stage public company. To this end, Mr. McDermott helped raise ~$190 million via private equity, debt, and an initial public offering. In August of 2018, Kala received NDA approval for Inveltys™, an internally developed drug for ocular indications. Before Joining Kala, Mr. McDermott worked at Allergan as Vice President, Global Business Development for the Eye Care and Drug Delivery business units. At Allergan, Mr. McDermott led efforts to license and acquire a variety of technologies and therapeutics including Lastacaft™, Acuvail™, Restasis® MultiDose™, Latisse™, and Abicipar. Before Joining Allergan, Mr. McDermott was Associate Director of Business Development at deCODE genetics (and before that he worked at Pfizer/Agouron in drug discovery and regulatory affairs. Mr. McDermott has a B.A. in biochemistry and molecular biology from UC Santa Cruz, a M.A. in molecular, cellular, and developmental biology from UC Santa Barbara, and a MBA from the University of San Diego.